Cognitive screening for lung cancer patients
Cognitive Screening in Lung Cancer Patients
This study is trying to see if lung cancer and its treatments affect thinking skills in patients during their first year after diagnosis.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Sponsor | European Institute of Oncology Academic / other |
| Locations | 1 site (Milan) |
| Trial ID | NCT06727370 on ClinicalTrials.gov |
What this trial studies
This study investigates cognitive impairment related to cancer and its treatment in patients with non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). It aims to assess the presence of cognitive deficits during the first year after enrollment using comprehensive neuropsychological assessments. The study focuses on understanding how lung cancer and its therapies may affect cognitive function over time.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older diagnosed with stage I to IV NSCLC or SCLC who can provide informed consent.
Not a fit: Patients aged 70 and older, those with brain metastases, or those with neurological or psychiatric disorders may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to better management strategies for cognitive impairment in lung cancer patients.
How similar studies have performed: While cognitive impairment in cancer patients has been studied, this specific focus on lung cancer and its treatments is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Small-cell and non-small-cell lung cancer (stage I, II, III, IV) * Age ≥ 18 years * Patients able to speak and read the local language(s) fluently * Acceptance and signature of informed consent Exclusion Criteria: * Age ≥ 70 * Presence of brain metastases * Patients with concomitant neurological or psychiatric disorders. * Patients undergoing brain radiotherapy * Previous diagnosis of lung cancer
Where this trial is running
Milan
- Istituto Europeo di Oncologia — Milan, Italy (Recruiting)
Study contacts
- Principal investigator: Gabriella Pravettoni — Istituto Europeo di Oncologia
- Study coordinator: Gabriella Pravettoni
- Email: gabriella.pravettoni@ieo.it
- Phone: +39025489731
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.